Literature DB >> 19349390

Role for interleukin-6 in COPD-related pulmonary hypertension.

Ari Chaouat1, Laurent Savale2, Christos Chouaid3, Ly Tu4, Benjamin Sztrymf2, Matthieu Canuet5, Bernard Maitre6, Bruno Housset7, Christian Brandt8, Philippe Le Corvoisier9, Emmanuel Weitzenblum5, Saadia Eddahibi4, Serge Adnot2.   

Abstract

BACKGROUND: Pulmonary artery remodeling triggered by alveolar hypoxia is considered the main mechanism of pulmonary hypertension (PH) in COPD patients. We hypothesized that the risk for PH in COPD is increased by an elevation in the proinflammatory cytokines interleukin (IL)-6, monocyte chemoattractant protein-1 (MCP-1), and IL-1beta, as well as by specific genetic polymorphisms of these cytokines.
METHODS: We assessed cytokine plasma levels and the polymorphisms G(-174)C IL-6, C(-511)T IL-1beta, and A(-2518)G MCP-1 in 148 COPD patients (recruited at two centers) with right heart catheterization data and 180 control subjects including smokers and nonsmokers. Human pulmonary artery smooth muscle cells (PA-SMCs) were cultured for IL-6 messenger RNA assays under normoxic and hypoxic conditions.
RESULTS: Patients with PH (mean pulmonary artery pressure [PAP], >or= 25 mm Hg) had lower Pao(2) and higher plasma IL-6 values than those without PH; there were no differences in terms of pulmonary function test results or CT scan emphysema scores. Plasma IL-6 correlated with mean PAP (r = 0.39; p < 0.001) and was included in a multiple stepwise regression analysis, with mean PAP as the dependent variable. In patients with the IL-6 GG genotype, the mean PAP value was significantly higher and PH was more common than in CG or CC patients (adjusted odds ratio, 4.32; 95% confidence interval, 1.96 to 9.54). Exposure to 4 h of hypoxia led to an about twofold increase in IL-6 messenger RNA in cultured human PA-SMCs.
CONCLUSIONS: Inflammation, most likely involving IL-6, may contribute substantially to PH complicating COPD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349390     DOI: 10.1378/chest.08-2420

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  67 in total

1.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

3.  MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD.

Authors:  Alan C-Y Hsu; Kamal Dua; Malcolm R Starkey; Tatt-Jhong Haw; Prema M Nair; Kristy Nichol; Nathan Zammit; Shane T Grey; Katherine J Baines; Paul S Foster; Philip M Hansbro; Peter A Wark
Journal:  JCI Insight       Date:  2017-04-06

4.  Relationship between coronary artery disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary disease.

Authors:  Muntecep Asker; Selvi Asker; Ugur Kucuk; Hilal Olgun Kucuk; Bulent Ozbay
Journal:  Int J Clin Exp Med       Date:  2014-12-15

5.  Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension.

Authors:  Michael G Risbano; Christina A Meadows; Christopher D Coldren; Tiffany J Jenkins; Michael G Edwards; David Collier; Wendy Huber; Douglas G Mack; Andrew P Fontenot; Mark W Geraci; Todd M Bull
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

6.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Pulmonary hypertension in a stable community-based COPD population.

Authors:  Vadim Fayngersh; Fotios Drakopanagiotakis; F Dennis McCool; James R Klinger
Journal:  Lung       Date:  2011-08-04       Impact factor: 2.584

8.  Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension.

Authors:  Soni Savai Pullamsetti; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.